Conference Correspondent

Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma

Conference Correspondent - Conference Correspondent, ASH 2016 - Multiple Myeloma

In a prior study, daratumumab (DARA) has demonstrated excellent clinical activity in combination with pomalidomide (POM) and dexamethasone (D) among relapsed or relapsed and refractory (R/RR) myeloma patients.1 While DARA is being evaluated in combination with other agents who are naïve to DARA or the backbone agent under evaluation, its utility is unclear among patients refractory to DARA or the combination agent.

This study evaluated 3 cohorts of patients receiving a combination of DARA-POM-D: cohort 1: patients naïve to both DARA and POM; cohort 2: patients refractory to DARA or POM; and cohort 3 (a subset of cohort 2): patients refractory to both DARA and POM. Researchers conducted a retrospective evaluation of 41 patients with relapsed or R/RR myeloma treated at a single site from January 2015 until July 2016.

Among the patients included in the analysis, the median age was comparable across cohorts at the time of DARA therapy initiation. All evaluable patients were lenalidomide-refractory, and 88% were bortezomib-refractory. Cohort 1 included 19 (46%) patients, cohort 2 included 22 (54%) patients, and cohort 3 included 12 (29%) patients. Median prior lines of therapy suggested that cohort 3 was a heavily pretreated group. High-risk cytogenetics for cohort 1:2:3 were 15.8% versus 31.8% versus 25%, respectively.

Common treatment-related adverse events (grade 3 or higher) included neutropenia (17 patients, 41%); anemia (12 patients, 29%); and thrombocytopenia (8 patients, 20%).

Patients in cohort 1 showed response rates of nearly 90%, and overall response rates of nearly 35% were seen in cohort 3. Progression-free survival was 7 months in all cohorts combined, and was 5 months in patients refractory to both DARA and POM (cohort 3). Notably, overall survival was 80% in cohort 3 after 8 months of follow-up.

These findings show that patients were able to recapture some of the response to agents to which they had become refractory, and lend support to further investigation of DARA-POM-DEX as a potential treatment option in heavily pretreated patients refractory to either or both DARA and POM.

Nooka AK, et al. ASH 2016. Abstract 492.

  1. Chari et al. ASH 2015.
Related Items
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Conference Correspondent published on June 6, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent
Last modified: May 17, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME